Early trials with FK 506 as primary treatment in liver transplantation by Todo, S et al.
Early Trials With FK 506 as Primary Treatment in Liver Transplantation 
S. TodD, J.J. Fung, A.J. Demetris, A. Jain, R. Venkataramanan, and T.E. Starzl 
FK 506 was first used clinically in February 1989. It 
was given in an effort to salvage chronically 
rejecting liver grafts in patients who also had such poor 
renal function that optimal doses of Cy A could not be 
given. l 
THE FIRST LIVER TRANSPLANT UNDER FK 506 
The second patient given the so-called rescue therapy had 
his liver graft salvaged, but eventually required emergency 
retransplantation because of thrombosis of a previously 
stenosed hepatic artery. This final graft was his sixth liver 
over a time span of 5 ¥3 years. The sixth transplantation, 
on July 2, 1989, was of historic interest because the new 
liver was the first one ever placed under immunosuppres-
sion solely with FK 506 to which low doses of steroids 
were added. This man is now 4 months postoperative after 
his last operation. He tolerated his sixth liver replacement 
with seeming ease despite poor renal function. His creat-
inine was 2.5 mg/dl at the time of his sixth liver retrans-
plantation and is 2.3 mg/dl now. He has long since been 
home. 
OTHER COMPLEX CASES 
Another patient whose first graft could not be rescued with 
FK 506 also was successfully retransplanted almost 2 
months ago, and a third patient became the recipient of a 
liver, pancreas, and kidney on August 16, 1989. All three 
of these patients are well, but the complexity of their 
indications for operation and the nature of their procedures 
made it difficult to compare their courses with anything in 
our recent experience. Consequently, we report the results 
of 20 consecutive primary liver transplantations performed 
between August 18,1989, and the end of September 1989. 
PRIMARY LIVER TRANSPLANTATION 
Case Material 
The individual cases are shown in Table I. None of these 
operations involved either retransplantation or the trans-
plantation of other organs. We picked from our past 
experience 20 other patients treated with conventional 
agents, including Cy A, and made certain comparisons. For 
inclusion as a control, it was required that there be survival 
for at least 1 full month. This meant that the control cases 
were culled, whereas the test cases were not. The controls 
were matched for age, sex, original disease, and degree of 
urgency as defined by the UNOS scoring system. 2 
Immunosuppression 
The management of the FK 506 patients was as described 
elsewhere in this symposium. A dose of 0.15 mg/kg FK 506 
was given intravenously over 1 hour after the new liver 
was revascularized. The intravenous dose thereafter was 
0.075 mg/kg/12 hours until the patient could eat. When a 
switch was made to the oral route, 0.15 mg/kg every 12 
hours, the intravenous and oral doses overlapped for a day 
or two. Trough levels after a few days tended to be about 
1 ng/ml or lower (Fig 1). One gram of methylprednisolone 
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Fig 1. Daily dose and blood levels of FK 506 in patients after 
liver transplantation. I.V., intravenous dose; Oral, oral dose. 
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Table 1. Summary of the First 20 Primary Liver Recipients Treated by FK 506 
Latest Liver Function Latest Immunosuppression 
Patient SGOT SGPT T. BIL FK 506 Steroid Histologic FOllow-up 
No. OLTX Age Sex Indication (U/L) (U/L) (mg/dl) (mglkgld) (mgld) Rejection Days Comment 
2108 55 F PBC 55 31 1.4 0.18 x 2 20 0 14 Died of MI 
2 2116 41 F PNC-B 37 45 0.5 0.18 x 2 a a 60 Discharged at 19 d 
3 2121 38 M PNC-C 56 72 0.2 0.15 x 2 5 a 50 Discharged at 12 d 
4 2128 39 M PNC-E 35 28 0.4 0.15 x 1 5 1 42 Discharged at 25 d 
5 2130 49 M SC 22 42 0.8 0.15 x 1 0 0 41 Discharged at 13 d 
6 2127 43 M PNC-C 82 129 0.6 0.15 x 1 a a 41 Discharged at 17 d 
7 2133 42 M BC 17 8 0.7 0.16 x 2 0 a 40 Discharged at lad 
8 2134 18 M Alagille's 20 18 0.4 0.18 x 1 5 a 41 Discharged at 18 d 
disease 
9 2138 41 F PBC 72 80 0.9 0.11 x 1 5 38 Discharged at 15 d 
10 2140 19 M SC 255 545 9.5 0.25 x 2 20 3 34 Hospitalized for rejection 
11 2143 33 F PBC 299 382 0.9 0.18 x 1 5 1 32 Readmitted for rejection 
12 2144 36 F PNC-C 27 49 0.3 0.15 x 1 5 a 31 Discharged at 11 d 
13 2145 38 M PNC-C 28 72 1.2 0.18 x 1 5 a 31 Discharged at 14 d 
14 2149 28 M Caroli's 25 34 0.9 0.15 x 2 10 28 Discharged at 14 d 
disease 
15 2150 41 M PNC-E 33 25 0.5 0.17 x '/2 d 5 a 27 Hospitalized 
16 2151 31 M SC 39 62 0.8 0.15 x 1 a 1 27 Discharged at 10 d 
17 2152 64 F PNC-E 54 194 0.6 0.15 x 1 10 0 25 Discharged at 8 d 
18 2153 55 M PNC-E 18 20 1.1 C.14;( 1 10 0 23 Hospitalized 
19 2154 43 F PNC-C 28 52 0.7 0.18 x 1 0 0 23 Discharged at 18 d 
20 2156 49 F BC 40 90 1.6 0.14 x 1 10 a 21 Discharged at 19 d 
OTLX, orthotopic liver transplantation; T. BIL, total bilirubin; PNC, primary biliary Cirrhosis; PNC-B, postnecrotic liver cirrhosis by B hepatitis; PNC-C, cryptogenic liver 
cirrhosis; PNC-E, alcoholic liver cirrhosis; SC, sclerosing cholangitis; BC, Budd-Chiari disease. 
steroid taper from 200 to 20 mg/d was carried out over 5 
days by 40-mg daily decrements. The FK 506-treated 
patients had a greatly reduced incidence of histopathologic 
rejection and almost no need for bolus or steroid recycle 
therapy or for other agents (Table 2). 
The steroid doses in the FK 506 patients versus the Cy A 
controls are summarized in Fig 2. The average dose in the 
19 FK 506 recipients who lived throughout the month was 
9 mg/d at the end of this time. In the controls, the dose 
averaged 19 mg/d. The summary data on al120 patients are 
given in Table 1. 
Mortality 
One of the 20 test patients died. This recipient, who had an 
old myocardial infarction, had primary pulmonary hyper-
tension with pulmonary artery pressures almost equal to 
the systemic blood pressure. The pulmonary hypertension 
was treated with prostaglandin infusions during the liver 
replacement and for 2 days afterward. Her recovery there-
after was unremarkable but, on the eve of her planned 
discharge, she developed signs of peritonitis. Her abdo-
men was explored, but there were no abnormalities. As the 
wound was closed, she had a cardiac arrest and could not 
be resuscitated. At autopsy, there was evidence of the old 
myocardial infarction, and she was found to also have a 
90% stenosis of the left anterior descending coronary 
artery. The other patients are alive and well. 
Liver Function 
Liver functions were followed daily for the first 2 weeks 
and irregularly thereafter. 
Bilirubin. The fall in bilirubin to normal was very rapid 
in the FK 506-treated patients, and this advantage was 
maintained throughout the study period. It averaged 1.0 
mg/dl at 1 month versus 5 mg/dl in the controls (Fig 3). 
SGOT. The SGOT after liver transplantation was simi-
lar in both groups of patients (Fig 4). 
Gamma-Guanosine Triphosphate. This canulicular en-
zyme measurement started higher during the first few days 
in the FK 506-treated patients, but it fell rapidly and, at all 
Table 2. Rejection and Immunosuppression 
Clinical and 
Histologic 
Rejection Steroids (Bolus/Re· 
Group N (%) cycle) (%) Imuran (%) OKT3 (%) 
FK506 20' 3 (15) 2 (10) 1 (5) 0(0) 
CyA 20 12 (60) 17 (85) 18 (90) 11 (55) 
'One patient died of MI and severe pulmonary hypertension at postoperative day 14 wnh well-functioning liver graft. 
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Fig 2. Differences of daily steroid dose given to FK 506 patients 
versus CyA patients. 
times after 2 weeks, the values were lower than in the 
conventional controls (Fig 5). The same pattern of a late 
advantage (after 2 weeks) as noted with the gamma-
guanosine triphosphate was also seen with the alkaline 
phosphatase (Fig 6). 
DISCUSSION 
The 20 patients who were the main object of our statistical 
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Fig 3. Postoperative changes of total bilirubin in FK 506 patients 
versus CyA patients. 
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Fig 4. Postoperative changes of the SGOT in FK 506 patients 
versus CyA patients. 
day of their operation. By the time of transplantation, 
there was no difficulty in recruiting participants in the 
study, since these new candidates had been exposed on an 
open ward to many of the patients whose livers had been 
rescued with FK 506. The very rapid convalescence of this 
new crop of fresh FK 506-treated patients, their low 
incidence of rejection, their low steroid requirements, and 
their early discharge from the hospital also became com-
mon knowledge. The rapidity and quality of convalescence 
of these first patients made it difficult to convince subse-
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Fig 5. Postoperative changes of the GGTP in FK 506 patients 
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Fig 6. Postoperative changes of ALP in the FK 506 patients 
versus CyA patients. 
quent patients to submit to so-called conventional immu-
nosuppressive regimens. The consequence was case ac-
crual to the FK 506 series in avalanche proportions. 
Almost all aspects of these cases will be considered in 
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other papers from this symposium. However, we would 
like to comment on one other detail, namely, the elimina-
tion of early graft failure (called by some "primary non-
function") in patients treated with FK 506. We have 
defined primary nonfunction rather loosely as the need for 
retransplantation in the first 15 days. The incidence of this 
kind of retransplantation in the best centers has been 15 to 
20%.3,4 Of the first 46 livers transplanted under FK 506 up 
to 2 weeks ago, including 3 retransplants, 38 primary livers 
used alone, and 5 livers used as parts of clusters or in other 
organ combinations, not a single one has had primary 
nonfunction. This means that many, if not most, of the 
mysterious perioperative graft failures collectively called 
primary nonfunction probably have a major immunologic 
etiology rather than reflecting a preservation injury or 
technical misadventure. 
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